Efficacy of Selpercatinib

Selpercatinib is approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and rearrangement during transfection (RET) gene fusions who should receive systemic therapy after treatment with immunotherapy and/or platinum-based chemotherapy. Serpatinib may also be used in adults and children 12 years and older with advanced or metastatic medullary thyroid carcinoma (MTC) with RET mutations who require systemic therapy and who have previously received sorafenib and/or lenvatinib.

Serpatinib is also indicated for the treatment of adults and children 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy after prior treatment with capozantinib and/or vandetinib. Adults and children 12 years and older with advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and are insensitive to radioactive iodine (if radioactive iodine is appropriate). Adults with RET gene fusion locally advanced or metastatic solid tumors that have progressed on or after prior systemic therapy or for whom satisfactory alternative treatment options are not available.

The original drug Serpatinib has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. Serpatinib marketed overseas The original drug has a US version and a European version. The price of the US version is about 150,000 yuan per box of 80mg*60 pills. The price of the European version of 80mg*56 pills per box is about 21,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also serpatinibgeneric drugs produced abroad. The specification produced by a Bangladesh pharmaceutical factory is 40mg*30 pills per box and the price is about 4,300 yuan (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs are basically the same as those of the original drug.